Maria Flores-Dieppa, MD
Family Medicine · Edison, NJNPI 1851399604
Payments from drug & device makers
Across 473 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$1K
- Novo Nordisk$1K
- Mylan Specialty L.p.$542
- Bayer$512
- Lilly USA, LLC$458
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,625100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $1,253 |
| Amgen | 76 | $1,058 |
| Novo Nordisk | 78 | $1,033 |
| Mylan Specialty L.p. | 32 | $542 |
| Bayer | 22 | $512 |
| Lilly USA, LLC | 33 | $458 |
| AbbVie(2 entities) | 26 | $401 |
| GSK | 10 | $202 |
| Abbott | 11 | $195 |
| Radius Health, Inc. | 11 | $181 |
| Esperion Therapeutics, Inc. | 13 | $172 |
| Amarin Pharma, Inc. | 5 | $156 |
| Pfizer | 10 | $152 |
| Boehringer Ingelheim | 11 | $151 |
| Sanofi-aventis U.S. LLC | 8 | $112 |
| Exact Sciences | 5 | $112 |
| Novartis | 7 | $111 |
| Johnson & Johnson | 6 | $88 |
| Phadia US Inc. | 6 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $72 |
| Kowa Pharmaceuticals America, Inc. | 5 | $71 |
| Dexcom, Inc. | 5 | $71 |
| Teva Pharmaceuticals USA, Inc. | 5 | $65 |
| Nestle Healthcare Nutrition Inc. | 4 | $59 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| QOL Medical, LLC | 3 | $44 |
| Merck | 3 | $43 |
| Paratek Pharmaceuticals, Inc. | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Astellas Pharma US Inc | 2 | $28 |
| Redhill Biopharma Inc. | 2 | $27 |
| Mannkind Corporation | 2 | $25 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Lupin Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,659 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $132,232 |
| JardianceEmpagliflozin | 84 | $79,250 |
| ProliaDenosumab | 44 | $74,662 |
| EliquisApixaban | 79 | $61,841 |
| JanuviaSitagliptin Phosphate | 42 | $47,066 |
| TrulicityDulaglutide | 29 | $37,204 |
| FarxigaDapagliflozin Propanediol | 28 | $33,427 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $27,748 |
| MyrbetriqMirabegron | 26 | $22,427 |
| MounjaroTirzepatide | 16 | $22,366 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $17,782 |
| BrilintaTicagrelor | 18 | $13,957 |
| Repatha SureclickEvolocumab | 25 | $13,856 |
| EntrestoSacubitril/Valsartan | 11 | $12,903 |
| XareltoRivaroxaban | 11 | $12,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,033 | $132,232122 claims |
| Boehringer IngelheimJardiance | $151 | $79,25084 claims |
| MerckJanuvia, Janumet | $43 | $74,81474 claims |
| AmgenProlia | $1,058 | $74,66244 claims |
| PfizerEliquis | $152 | $61,84179 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $458 | $59,57045 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $1,253 | $52,99869 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $202 | $31,50452 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $22,42726 claims |
| AbbVieLinzess, Synthroid | $401 | $13,43534 claims |
| NovartisEntresto | $111 | $12,90311 claims |
| Johnson & JohnsonXarelto | $88 | $12,08811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Edison
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.